To examine the role of vascular endothelial growth factor (VEGF) in the pathogenesis of high-altitude pulmonary edema (HAPE), we measured the concentrations of VEGF in venous serum and bronchoalveolar lavage fluid (BALF) in patients with HAPE and healthy volunteers. The VEGF in venous serum of the patients was normal at admission while significantly increased at recovery.
INTRODUCTION
High-altitude pulmonary edema (HAPE) is a life-threatening condition defined as non-cardiogenic pulmonary edema (11) . It affects healthy people after rapid ascent to altitudes above 2,500 meters (10, 13) . Although exaggerated pulmonary hypertension was suggested as important in the pathogenesis of HAPE (9), it is not sufficient to trigger pulmonary edema (24) . Accumulating evidence concerning inflammation and increased vascular permeability has been clearly revealed by bronchoalveolar lavage (BAL) studies in patients with HAPE, suggesting that additional mechanisms play a role in this condition (14, 15, 25, 26, 30) .
Vascular endothelial growth factor (VEGF) is a potent endothelial-cell-specific mitogen and permeability factor, known to be involved in vascular basement membrane destruction and angiogenesis (6, 8, 16) . Overexpression of VEGF in the lung induces an increased pulmonary vascular permeability resulting in pulmonary edema (12) . In addition, VEGF has been shown to be markedly up-regulated in the hypoxic condition (5, 17, 20, 31) . Recent studies suggested that VEGF production in hypoxia might be involved in high-altitude cerebral edema (HACE) (27, 34) . HAPE sometimes occurs in conjunction with HACE. The increased capillary permeability is likely to be a crucial mechanism in both disorders (15, 25, 26) . We hypothesized that VEGF might also play some pathophysiological part in the development of HAPE.
In the present study, we measured the concentrations of VEGF in venous serum and BAL fluid (BALF) in patients with HAPE at admission and during the recovery stage, respectively, which were compared with those in healthy young volunteers.
METHODS

Subjects.
The nine patients with HAPE enrolled in the study were all nonsmoking male climbers, with an JAP-00575-2002.R2. 3 average age of 36.9 years. They had been born and resided at low altitude. They had been rescued while climbing in the Japan Alps and transported to our institution, Shinshu University Hospital (610 meters above sea level). The altitude at the onset of HAPE ranged from 2,350 to 3,190 meters above sea level. The average duration of the HAPE victims at high altitude was 3-4 days. We diagnosed HAPE based on the following criteria (10): onset at high altitude of the typical symptoms, including cough and dyspnea at rest; absence of infection; presence of pulmonary rales and cyanosis; disappearance of symptoms and signs within three days of the start of treatment with bed rest and supplemental oxygen; and chest roentgenographic infiltrates consistent with pulmonary edema. All subjects had met the criteria at the onset of the disorder, and two subjects were also comatose and showed the condition of HACE. All recovered promptly during hospitalization without the intervention of mechanical ventilation.
We recruited five nonsmoking males, with an average age of 21.0 years, as a control group. They had all been born and resided at low altitude. They had no history of cardiopulmonary problems and were taking no other medications at the time of this study. All subjects gave informed consent, and the study protocol was approved by the Institutional Committee on Human Research of our School of Medicine.
Peripheral blood.
Venous blood samples from the patients with HAPE were drawn into serum tubes containing beads and clot activator at the time of admission before oxygen administration, and at the moment of discharge (on the 6 th -10 th day after admission). Concomitantly, the blood samples were also obtained from the five controls. The samples were kept at room temperature for 30 minutes prior to centrifugation at 3,000 revolutions per minute (rpm) for 10 minutes, then the supernatants were kept frozen at -70 Cº until assayed.
The serum VEGF was measured using a quantitative sandwich enzyme-linked immuno-sorbent In addition, the circulating white blood cell (WBC) count and C reactive protein (CRP) level of the patients were measured at admission as well as at discharge.
BALF.
BAL was performed in the patients with HAPE within 12 hours after admission, and at the time of discharge (on the 6 th -10 th day after admission). Following subcutaneous injection of atropine (0.5 mg)
and pethidine hydrochloride (0.5 mg/kg), 2% lidocaine solution was sprayed in the oral pharynx and upper airway for local anesthesia. A sterile fiberoptic bronchoscope (Olympus BF 1T, Olympus, Tokyo, Japan) was wedged in the B4 or B5 segmental bronchus. Three 50 ml aliquots of sterile normal saline warmed to 37ºC were instilled successively into the lobe, and each was in turn removed by gentle suction. The mean percent retrieval of the instilled saline was 57.5 ± 5.0% at admission and 59.0 ± 2.3% at recovery. The lavage fluid was filtered through gauze. One aliquot was set aside for counting the number of total cells. Another aliquot was spun in a cytometer at 500 rpm for 5 min and stained by the May-Grunwald-Giemsa method to identify cells in a population of 200 cells. The remaining aliquot was centrifuged to remove cellular elements, and was stored frozen at -70ºC for biological analysis at a later time. The same method was performed in the control subjects. The mean percent retrieval of the instilled saline was 60.3 ± 2.9%.
VEGF was measured with the ELISA method in the supernatant samples of the BALF as described above. We also measured the concentrations of total protein and albumin in the BALF of the patients and controls using the pyrogallol red method and the immunoturbidimetric assay, respectively (14, 15) .
Statistical analysis.
Values are expressed as the mean ± SE. The two-tailed Student's t test was used for the comparisons of the measurements between the admission and recovery within the patients, as well as between the HAPE patients and controls within all the subjects. A P value < 0.05 was considered statistically significant.
RESULTS
Measurements in peripheral blood.
The circulating white blood cell counts (13,319 ± 710 /µl) and C reactive protein (CRP) level (3.64 ± 0.83 mg/dl) were elevated in all patients with HAPE at admission, while these values were returned to the normal range at discharge. Fig. 1 shows the concentrations of VEGF in serum in both groups. The VEGF of the HAPE patients at recovery (423.7 ± 44.7 pg/ml) was significantly increased compared to that at admission (260.7 ± 38.7 pg/ml, P < 0.05), although there was no significant difference of VEGF between the HAPE at admission and the controls (260.7 ± 38.7 pg/ml versus 228.8 ± 50.5 pg/ml, P > 0.05).
Measurements in BALF.
For patients with HAPE, significantly elevated values were total cell count (348.1 ± 71.0 x 10 3 /ml versus 42.6 ± 5.4 x 10 3 /ml, P < 0.05), alveolar macrophages (123.8 ± 19.0 x 10 3 /ml versus 36.9 ± 5.3 x 10 3 /ml, P < 0.01) and neutrophils (119.9 ± 19.2 x 10 3 /ml versus 0.6 ± 0.2 x 10 3 /ml, P < 0.001), compared with those in control subjects. In addition, the total protein (342.6 ± 62.5 mg/dl versus 5.4 ± 0.7 mg/dl, P < 0.005) and albumin (2267.2 ± 298.1 µg/ml versus 29.6 ± 1.4 µg/ml, P < 0.0005) levels were significantly higher in patients with HAPE than the controls. At recovery, all these elevated JAP-00575-2002.R2. 6 values in HAPE were normalized as in controls. The bacteriological examinations of the BALF yielded negative results in all samples. Fig. 2 shows the concentrations of VEGF in the BALF in both groups. VEGF was detectable in all samples. The VEGF of the patients at admission (42.8 ± 9.9 pg/ml) was markedly deprived comparing with that of controls (265.2 ± 34.9 pg/ml, P < 0.00005). Subsequently, the deprived VEGF was gradually restored at the recovery stage (79.8 ± 5.6 pg/ml), which, however, could not reach to a significance comparing with that at admission.
DISCUSSION
The elevated values of circulating white blood cell count and CRP in the peripheral blood accompanied with the increased levels of total cell count and protein in the BALF in the patients with HAPE were similar to those in previous studies (14, 15, 25, 26) , which reveals a transient inflammatory process during the early stage of HAPE. The most noteworthy finding in the present study was that the concentration of VEGF in the BALF of patients was markedly deprived compared with that in controls, indicating the production of VEGF is insulted in the lung of the patients. In addition, the deprived VEGF in the BALF of the patients was improved gradually, following a similar VEGF dynamics in venous serum during the stage of recovery.
VEGF is a potent mitogenic and permeability factor predominantly targeting endothelial cells (6, 16) . VEGF expression is up-regulated by hypoxia (5, 17, 20, 31) , and its role in hypoxia-induced angiogenesis has been extensively studied in a variety of disease entities. Xu and Severinghaus (34) showed that the transcription of VEGF and the production of VEGF protein in the rat brain were up-regulated during the first week of hypoxia. They hypothesized that the angiogenesis process induced by VEGF might be involved in the development of HACE. Overexpression of VEGF was also proposed to contribute to the pathogenesis of hypoxic pulmonary hypertension (5, 32) and increased JAP-00575-2002.R2. 7 pulmonary vascular permeability (6, 12), both of which are principal mechanisms in HAPE (9, 11). We measured the VEGF in peripheral blood and BALF in the HAPE patients at the early stage, and showed the levels of VEGF were unexpectedly depressed in BALF although they remained unchanged in peripheral blood. Since all blood samples were obtained before oxygen administration, all BAL studies were performed within 12 hours after admission, and no patient received mechanical ventilatory intervention that could interfere with the biological functions of the lung, so the present findings appear to reflect the lung condition of HAPE at the early stage.
Recently, several investigations were conducted for studying the pathophysiological role of VEGF in HAPE, finding that the VEGF at high altitude was not elevated in association with acute mountain sickness (AMS), HAPE or hypoxia, concluding that VEGF might not mediate critically pulmonary permeability during the earliest time at high altitude (18, 22, 33) . However, except for one measurement of VEGF in the pulmonary capillaries (33) , all other measurements were the VEGF concentration in the systemic circulation. Therefore, the pathophysiological role of VEGF in the HAPE lung remains to be clarified. Despite being characterized by endothelial-cell-specificity, VEGF is expressed and released by epithelial cells that are in close proximity to the microvasculature in the highly vascularized lung tissues (4). Studies elsewhere showed that the VEGF mRNA and protein were abundant in the distal airway epithelial cells of the development and adult lungs and important in driving the development of the pulmonary capillary bed and ultimately the air-blood barrier (3). The high concentration of VEGF in BALF in the lung of controls revealed in this study implied that VEGF might play an essential role in the maintenance of physiological function of lung. Based on those above, we suspect that the deprivation of VEGF in the lung of HAPE at admission might disturb the air-blood barrier function resulting in increased pulmonary vascular permeability while the restoration of VEGF in the lung during recovery could repair the dysfunctional air-blood barrier and protect against increased permeability.
The highlighted point of the present study was to focus on the pathophysiological role of VEGF in JAP-00575-2002.R2. 8 the lung, the insulted organ of HAPE. Among normal tissues, the lung has a relatively high VEGF message abundance (2) . The VEGF concentration in BALF of nonsmoking normal subjects, detected by ELISA, was reported to be between 67 and 289 pg/ml (mean = 141 pg/ml) by Boussat et al. (4) pneumocytes and capillary endothelial cells were damaged in the HAPE lung (7, 29) . These findings suggest that VEGF is less likely to be involved in the pathogenesis of pulmonary edema formation as a permeability factor. However, supported by the present evidence of the increased VEGF in both the systemic and pulmonary circulations during the recovery stage of HAPE, it is suggested that VEGF is probably related to the repair of the impaired cellular layer. Since the findings derived from animal study suggested that alveolar epithelium was the primary site of increased VEGF mRNA abundance in the recovering lung injured by acute hyperoxia, the type II cells might regulate the proliferation of subjacent endothelium and contribute to microvascular endothelial repair after the damage (19) .
Endothelial cells are involved in several key processes in restitution of the air-blood barrier in alveoli (1) . The regulations of angiogenesis and endothelium repair in the lung are probably crucial to satisfactory healing (4). The dramatic response to oxygen therapy in HAPE patients at an early stage suggests that the cellular biological impairment in lung of HAPE is reversible (23) . Taken together, it is suggested that this re-released VEGF in the BALF and systemic circulation plays certain role in the marked recovery of HAPE.
In summary, a marked deprivation of VEGF in BALF of the HAPE patients at admission following its gradual restoration at recovery accompanied with similar dynamics in peripheral blood was observed. It is suggested that VEGF appears less likely to have a critical part in the pathogenesis of HAPE, but rather an important role in the repair process.
JAP-00575-2002.R2. 16 Fig. 1 . The concentrations of vascular endothelial growth factor (VEGF) in venous serum in patients with high-altitude pulmonary edema (HAPE) at admission and at discharge, and in control subjects.
LEGENDS FOR ILLUSTRATIONS
Values are means ± SE. * P < 0.05 compared with the HAPE group at admission. # P < 0.05 compared with the control group. 
